Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Our Participating Medicines

The Genentech medicines supported by the Genentech Patient Foundation are:

  • ACTEMRA® (tocilizumab)
  • ACTIVASE® (alteplase)
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • CATHFLO ACTIVASE® (alteplase)
  • COTELLIC® (cobimetinib)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • HERCEPTIN HYLECTA® (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PEGASYS® (peginterferon alfa-2a)
  • PERJETA® (pertuzumab)
  • PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
  • POLIVYTM (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREKTM (entrectinib)
  • TARCEVA® (erlotinib)
  • TECENTRIQ® (atezolizumab)
  • TNKASE® (tenecteplase)
  • VENCLEXTA® (venetoclax)
  • XELODA® (capecitabine)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)

Please Note: At this time, the Genentech Patient Foundation supports the following medicines through a separate process:

  • CELLCEPT® (mycophenolate mofetil)
  • FUZEON® (enfuvirtide)
  • NUTROPIN AQ® (somatropin)
  • VALCYTE® (valganciclovir hydrochloride)

Learn more about support programs for these Genentech medicines here.

If you have been prescribed a participating medicine, you may qualify for support from the Genentech Patient Foundation. View the 'See If You Qualify' page to determine eligibility.

Support for Genentech medicines not listed above:

If you do not see your medicine listed, please contact our Patient Resource Center at 1 (877) GENENTECH (436-3683) for more information.